Is Amicus Therapeutics, Inc. overvalued or undervalued?

As of 7 November 2016, the valuation grade for Amicus Therapeutics, Inc. has moved from does not qualify to risky, indicating a significant change in the company's perceived financial stability. The company appears to be overvalued, particularly given its current Price to Book Value of 9.80 and an EV to EBITDA ratio of 36.52, which are considerably high compared to industry norms. Additionally, the company's ROE stands at -13.55%, reflecting ongoing challenges in generating shareholder returns.
In comparison to peers, Amicus Therapeutics has a P/E ratio of -68.09, while Insmed, Inc. shows a less extreme P/E of -21.43, and Perrigo Co. Plc has an even more negative P/E of -130.48. Notably, ACADIA Pharmaceuticals, Inc. and Organon & Co. are classified as very attractive, with P/E ratios of 16.67 and 2.90, respectively, which further emphasizes the relative overvaluation of Amicus. The company's stock has underperformed significantly against the S&P 500, with a year-to-date decline of 39.38% compared to a modest 2.44% increase in the index, reinforcing the assessment of overvaluation.